{"title":"Politics in wine and medicine.","authors":"Shaun R McCann","doi":"10.1038/s41409-024-02411-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02411-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M Luz Uria-Oficialdegui, Victor Quintero, M Isabel Benitez-Carabante, David Bueno, Maria Trabazo, Monica Lopez-Duarte, Laura Alonso, Melissa Panesso, Laura Murillo-Sanjuan, Carolina Fuentes, Graciela Gomez, Marta Gonzalez-Vicent, Jaime Verdu, Cristina Diaz-de-Heredia
{"title":"Accurate donor and recipient selection and a short time to transplant offer excellent outcomes in upfront hematopoietic stem cell transplantation from matched unrelated donors for pediatric severe aplastic anemia and refractory cytopenia of childhood. A study of the Spanish Pediatric Group for Hematopoietic Cell Transplantation and Cell Therapy (GETH-TC).","authors":"M Luz Uria-Oficialdegui, Victor Quintero, M Isabel Benitez-Carabante, David Bueno, Maria Trabazo, Monica Lopez-Duarte, Laura Alonso, Melissa Panesso, Laura Murillo-Sanjuan, Carolina Fuentes, Graciela Gomez, Marta Gonzalez-Vicent, Jaime Verdu, Cristina Diaz-de-Heredia","doi":"10.1038/s41409-024-02406-z","DOIUrl":"https://doi.org/10.1038/s41409-024-02406-z","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mats Brune, Thomas Kiss, Harald Anderson, Malin Nicklasson, Robert Delage, Jürgen Finke, Tobias Gedde-Dahl, Josée Hébert, Martin Höglund, Ain Kaare, Vladimir Lazarevic, Lars Möllgård, Kari Remes, David Ritchie, Alexandros Spyridonidis, Mitchell Sabloff, Ruth Spearing, Elisabeth Wallhult, Per Ljungman
{"title":"Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.","authors":"Mats Brune, Thomas Kiss, Harald Anderson, Malin Nicklasson, Robert Delage, Jürgen Finke, Tobias Gedde-Dahl, Josée Hébert, Martin Höglund, Ain Kaare, Vladimir Lazarevic, Lars Möllgård, Kari Remes, David Ritchie, Alexandros Spyridonidis, Mitchell Sabloff, Ruth Spearing, Elisabeth Wallhult, Per Ljungman","doi":"10.1038/s41409-024-02408-x","DOIUrl":"https://doi.org/10.1038/s41409-024-02408-x","url":null,"abstract":"<p><p>The aim of this prospective, international multicenter, pseudorandomized study comparing RICT HCT to standard-of-care chemotherapy in intermediate- or high-risk AML patients 50-70 years using the donor versus no-donor concept. Part 1 included only patients with potential family donors (RD) at the date of HLA-typing of the first potential sibling or CR-date, if later. Part 2 allowed the inclusion of patients without a possible sibling donor using the start of an unrelated donor (URD) search as inclusion date. 360 patients were registered and 309 analyzed. The median follow-up was 47 months (1-168). There was no difference in overall survival (OS) between the RD (n = 124) and the Control (n = 77) groups (p = 0.50, 3-year OS RD: 0.41(95% CI; 0.32-0.50); Controls: 0.49 (95% CI; 0.37-0.59)). The main cause of death was relapse (67% RD; 88% Controls). In Part 2, the 3-year OS was 0.60 (95% CI 0.50-0.70) for URD-HCT (n = 86) and 0.37 (95% CI 0.13-0.62) for Controls (n = 20), respectively (p = 0.10). When analyzing transplanted patients (Part 2), the OS at 3-years was higher for URD-HCT than RD-HCT (0.67 (0.55-0.76) vs. 0.42 (0.26-0.57; p = 0.005). This study doesn't support elderly HLA-identical siblings as donors for older AML patients undergoing a RICT allogeneic HCT in first CR.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Megan Othus, Domitilla Baccon, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M Sandmaier, Chris Davis, Ryan S Basom, Roland B Walter
{"title":"Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.","authors":"Megan Othus, Domitilla Baccon, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M Sandmaier, Chris Davis, Ryan S Basom, Roland B Walter","doi":"10.1038/s41409-024-02407-y","DOIUrl":"https://doi.org/10.1038/s41409-024-02407-y","url":null,"abstract":"<p><p>Outcomes of adults with AML after allografting vary widely. While numerous covariates have been associated with relapse, non-relapse mortality (NRM), and/or shorter survival, the impact of incomplete blood count recovery before transplantation has remained unclear. To address this uncertainty, we examined all adults with AML or MDS/AML who received an allograft in first or second remission between 2006 and 2023 at a single institution. Of 1264 patients, 891 (70%) met criteria for CR, whereas 291 (23%), 24 (2%), and 58 (5%) were classified as CRh, CRi, and morphologic leukemia-free state (MLFS), respectively. CR, CRh, CRi, and MLFS patients differed significantly regarding demographics, disease biology, pre-transplant measurable residual disease, and types of transplants. After multivariable adjustment, outcomes for CRh and CRi patients were not significantly different from each other or from those of CR patients. In contrast, outcomes of MLFS patients were substantially worse than those of CR and CRh patients, with significantly higher risk of NRM and relapse, and significantly shorter relapse-free and overall survival. Similar results were obtained in several distinct subsets. Together, our analysis provides empiric evidence for the importance of distinguishing MLFS from CR and CRh patients for optimized risk assessment and, possibly, individualized treatment decision making.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Urban Novak, Jarl E. Mooyaart, Michael Daskalakis, Christof Scheid, Ludovic Gabellier, Ibrahim Yakoub-Agha, Ron Ram, Edouard Forcade, Lucía López-Corral, Emma Nicholson, Eugenio Galli, Friedrich Stölzel, Wolfgang Bethge, Eva Maria Wagner-Drouet, Jorinde D. Hoogenboom, Stephan Mielke, Caroline Arber, Federico Simonetta, Christian Chabannon, Jürgen Kuball, Annalisa Ruggeri, Florent Malard
{"title":"Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT","authors":"Urban Novak, Jarl E. Mooyaart, Michael Daskalakis, Christof Scheid, Ludovic Gabellier, Ibrahim Yakoub-Agha, Ron Ram, Edouard Forcade, Lucía López-Corral, Emma Nicholson, Eugenio Galli, Friedrich Stölzel, Wolfgang Bethge, Eva Maria Wagner-Drouet, Jorinde D. Hoogenboom, Stephan Mielke, Caroline Arber, Federico Simonetta, Christian Chabannon, Jürgen Kuball, Annalisa Ruggeri, Florent Malard","doi":"10.1038/s41409-024-02401-4","DOIUrl":"10.1038/s41409-024-02401-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"59 11","pages":"1631-1634"},"PeriodicalIF":4.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.","authors":"Haixiao Zhang, Wenwen Guo, Jiali Wang, Ni Lu, Xinhui Zheng, Qi Sun, Yonghui Xia, Rongli Zhang, Xin Chen, Qiaoling Ma, Donglin Yang, Aiming Pang, Jialin Wei, Yi He, Sizhou Feng, Mingzhe Han, Weihua Zhai, Erlie Jiang","doi":"10.1038/s41409-024-02402-3","DOIUrl":"https://doi.org/10.1038/s41409-024-02402-3","url":null,"abstract":"<p><p>Bone marrow fibrosis (BMF) of unknown etiology was common in hematological malignancies, but its prognostic value for acute myeloid leukemia (AML) is unclear. We interrogated data from 532 newly diagnosed subjects with AML receiving allogeneic hematological stem cell transplantation to evaluate the prognostic impact of BMF on transplant outcomes. Using the European consensus on the grading of BMF at diagnosis, 255 (48%) subjects were BMF-0, 209 (39%), BMF-1 and 68 (13%), BMF-2-3. Subjects with BMF-2-3 had poor overall survival (P < 0.001), disease-free survival (P < 0.001) and a higher incidence of relapse (CIR, P < 0.001). Multi-variable analyses in subjects achieving pre-transplant complete remission showed BMF-2-3 was an independent risk factor for CIR (Hazard Ratio [HR] = 2.17, (95% CI, 1.11, 4,24); P = 0.02). Furthermore, BMF-2-3 group showed delayed neutrophil and platelet engraftment and delayed B cell recovery post-transplantation. These findings demonstrate the significance of BMF in transplant outcomes and attract more attention to AML with BMF.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Silfverberg, Christina Zjukovskaja, Yassine Noui, Kristina Carlson, AutoMS-Swe Investigators, Joachim Burman
{"title":"BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis","authors":"Thomas Silfverberg, Christina Zjukovskaja, Yassine Noui, Kristina Carlson, AutoMS-Swe Investigators, Joachim Burman","doi":"10.1038/s41409-024-02397-x","DOIUrl":"10.1038/s41409-024-02397-x","url":null,"abstract":"The most widely used conditioning regimens in autologous haematopoietic stem cell transplantation (ASCT) for multiple sclerosis (MS) are BEAM with anti-thymocyte globulin (ATG) and high-dose cyclophosphamide with ATG (Cy/ATG). In this retrospective study, we compare efficacy and safety of these regimens when used for relapsing-remitting MS. We assessed 231 patients treated in Sweden before January 1, 2020. The final cohort comprised 33 patients treated with BEAM/ATG and 141 with Cy/ATG. Prospectively collected data from the Swedish MS registry were used for efficacy, and electronic health records for procedure-related safety. The Kaplan–Meier estimate of ‘no evidence of disease activity’ (NEDA) at 5 years was 81% (CI 68–96%) with BEAM/ATG and 71% (CI 63–80%) with Cy/ATG, p = 0.29. Severe adverse events were more common with BEAM/ATG, mean 3.1 vs 1.4 per patient, p = <0.001. Febrile neutropaenia occurred in 88% of BEAM/ATG patients and 68% of Cy/ATG patients, p = 0.023. Average hospitalisation was 3.0 days longer in BEAM/ATG patients from day of stem-cell infusion, p < 0.001. While both regimens showed similar efficacy, BEAM/ATG was associated with more severe adverse events and prolonged hospitalisation. In the absence of randomised controlled trials, Cy/ATG may be preferable for ASCT in patients with relapsing-remitting MS due to its favourable safety profile.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"59 11","pages":"1601-1610"},"PeriodicalIF":4.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-024-02397-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Curtis M. Marcoux, Amin M. Alousi, Jin Im, Laquisa C. Hill, Portia Smallbone, Uday Popat, Chitra Hosing, Partow Kebriaei, Amanda Olson, Rohtesh Mehta, George Chen, Muzaffar Qazilbash, Elizabeth Shpall, Richard C. Champlin, Rima M. Saliba
{"title":"Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease","authors":"Curtis M. Marcoux, Amin M. Alousi, Jin Im, Laquisa C. Hill, Portia Smallbone, Uday Popat, Chitra Hosing, Partow Kebriaei, Amanda Olson, Rohtesh Mehta, George Chen, Muzaffar Qazilbash, Elizabeth Shpall, Richard C. Champlin, Rima M. Saliba","doi":"10.1038/s41409-024-02393-1","DOIUrl":"10.1038/s41409-024-02393-1","url":null,"abstract":"Minnesota acute graft versus host disease (AGVHD) risk score is a validated tool to stratify newly-diagnosed patients into standard-risk (SR) and high-risk (HR) groups with ~85% having SR AGVHD. We aimed to identify factors for further risk-stratification within Minnesota SR patients. A single-center, retrospective analysis of consecutive patients between 1/2010 and 12/2014 was performed. Patients who developed AGVHD within 100 days and treated with systemic corticosteroids were included (N = 416), 356 (86%) of which were Minnesota SR and 60 (14%) had HR AGVHD. Isolated upper gastrointestinal (GI) AGVHD patients had significantly better day 28 and 56 CR/PR rates (90% vs. 72%, p = 0.004) and (83% vs 66%, p = 0.01), respectively, and lower 1-year non-relapse mortality (NRM; 10% vs. 22%; HR 0.4, p = 0.03). Lower GI AGVHD had less favorable outcomes with 1-year NRM of 40% (HR 2.1, p = 0.001), although CR/PR rates were not statistically different. In multivariate analysis, lower GI involvement (HR 2.6, p < 0.001), age ≥ 50 (HR 2.9, p < 0.001) and HCT-CI > 3 (HR 2.1, p = 0.002) predicted for 1-year NRM. Heterogeneity within Minnesota SR patients requires consideration in clinical trials, as distinct outcomes are observed in those with isolated upper GI and lower GI AGVHD, highlighting the importance of stratification in clinical trial design.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"59 11","pages":"1594-1600"},"PeriodicalIF":4.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Poveda-García, Estela Ruiz, María José Moreno, Ignacio Español, Andrés Sánchez-Salinas, Ana María García-Hernández, Miguel Blanquer, Inmaculada Martínez, María Sánchez-Villalobos, María Carmen García Garay, Eduardo Salido, Ángela Heredia, Begoña Navarro-Almenzar, Jorge Monserrat, José Antonio Sánchez-Salas, Antonio José Martínez-Mellado, Alfredo Minguela, José Antonio Campillo, Ruth López-Hernández, José Antonio Galián, José M. Moraleda, Vanessa Roldán, Valentín Cabañas
{"title":"Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis","authors":"Andrea Poveda-García, Estela Ruiz, María José Moreno, Ignacio Español, Andrés Sánchez-Salinas, Ana María García-Hernández, Miguel Blanquer, Inmaculada Martínez, María Sánchez-Villalobos, María Carmen García Garay, Eduardo Salido, Ángela Heredia, Begoña Navarro-Almenzar, Jorge Monserrat, José Antonio Sánchez-Salas, Antonio José Martínez-Mellado, Alfredo Minguela, José Antonio Campillo, Ruth López-Hernández, José Antonio Galián, José M. Moraleda, Vanessa Roldán, Valentín Cabañas","doi":"10.1038/s41409-024-02404-1","DOIUrl":"10.1038/s41409-024-02404-1","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"59 11","pages":"1625-1627"},"PeriodicalIF":4.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
